Pfizer agrees $630m deal to harness Voyager’s gene therapy tech

Voyager Therapeutics has just landed a new gene therapy alliance with Pfizer that could go some way towards easing the pain of losing three other partners in the space of a couple of years.

Pfizer is paying Voyager $30 million upfront to get access to its TRACER adeno-associated virus (AAV) vector technology, which aims to improve the safety of gene therapies – a field that has suffered a string of safety scares in the last few months.

Read the source article at pharmaphorum.com
2021-10-06 14:31:58